LPA (lysophosphatidic acid), a pro-fibrotic, inflammatory mediator and also a downstream metabolite of Phospholipase A2 (PLA2) signaling was found to be increased in both BAL fluid of IPF patients and bleomycin-treated mice. This evidence concerns the gene PLA2G6 and idiopathic pulmonary fibrosis.